Business UpdateJul 10, 2026, 06:13 AM
Alamar NULISA Platform Featured in 140+ AAIC Presentations
AI Summary
Alamar Biosciences announced that its NULISA platform will be featured in over 140 poster and session presentations at the Alzheimer's Association International Conference (AAIC) from July 12-15. This significant increase in presentations, over four times the previous AAIC, highlights the widespread adoption of NULISA and ARGO HT technology in Alzheimer's research. Alamar will also host a workshop to showcase new data on its eMTBR-Tau and BD-pTau217 assays, demonstrating improved detection and staging of Alzheimer's disease.
Key Highlights
- Alamar's NULISA platform featured in over 140 poster and session presentations at AAIC.
- This volume is over four times the number of presentations at the previous AAIC.
- Alamar will host a workshop titled "Beyond p-tau217" on July 14 at AAIC.
- Workshop to showcase new data on eMTBR-Tau and BD-pTau217 assays.
- These assays measure over 220 disease-related proteins on a single NULISAseq panel.
- Evidence shows combined biomarkers improve discrimination across Alzheimer's continuum.
- NULISA platform is applicable across presymptomatic, prodromal, and diagnosed Alzheimer’s populations.
Price Impact
More from ALMR